Researchers Reported Positive Phase 1 VYD2311 Results
A study of the monoclonal antibody VYD2311 for COVID-19 prevention demonstrated safety and tolerability in 40 participants.
Updated on Oct. 13, 2026 in Diseases — General
Live Poll
Do you generally trust the safety findings reported for new medical treatments in early-stage trials?
On September 17, 2026, researchers presented findings from a phase 1 trial of the monoclonal antibody VYD2311. The study found that the drug was safe and tolerable, with all observed adverse events classified as mild or moderate in severity.
Why it matters
The successful phase 1 trial provides the safety data necessary to advance the antibody into larger studies for COVID-19 prevention. It marks a critical step in evaluating alternative administration methods for preventative therapies.
The study included 40 participants randomized at an 8 to 2 ratio, evaluating doses including 2000 mg and 4500 mg IV, 1000 mg IM, and 1250 mg SC. Researchers observed a 40.6% rate of drug-related adverse events among those in the intervention groups.
The players
VYD2311
This is a monoclonal antibody currently being developed as a preventative treatment for COVID-19.
The details
Healthy participants received the VYD2311 antibody or a placebo via intravenous infusion, intramuscular injection, or subcutaneous injection. No adverse events led to study discontinuation or death during the evaluation of the various dosing regimens.
Timeline
Study results were presented at a clinical rheumatology congress in Huntington Beach from September 17-20, 2026.
Health Landscape
The clinical evaluation of VYD2311 reflects the ongoing scientific shift toward developing long-acting monoclonal antibodies for viral prevention. This development continues the broader medical trend of diversifying dosing routes to enhance patient accessibility and therapeutic uptake.
The phase 1 study suggests that VYD2311 may eventually offer patients more flexible administration options, such as intramuscular injections. Patients should note that a phase 3 study of these dosing regimens is currently underway to further establish safety and efficacy.
The takeaway
This trial confirms that the antibody maintains a favorable safety profile across multiple delivery methods. Future results from the ongoing phase 3 study will be essential to determine if this therapy effectively prevents COVID-19 in diverse groups.
Further reading
For more information on medical research, visit the Diseases — General section.
More information
View the full details of the study on the ClinicalTrials.gov study identifier.
Source note: This article includes information reported by Renal and Urology News.
Live Poll
Do you generally trust the safety findings reported for new medical treatments in early-stage trials?
